CIPHER PHARMACEUTICALS INC chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.82
Dividend & YieldN/AC$ (N/A)
Beta 1.26
Market capitalization 81.88M
Operating cash flow 11.48M
ESG Scores unknown

Company description

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug. The company's licensed products comprise CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and Conzip/Durela (CIP- Tramadol), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. Its pipeline products include Trevyent, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension; CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for the treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Oakville, Canada.

Sector: Healthcare - Industry: Drug Manufacturers—Specialty & Generic

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -6.28M -1.99M 480k -1.09M
Total Cashflows From Investing Activities -24.48M -1.46M -760k
Net Borrowings -834k -9.85M -7.93M -828k
Total Cash From Financing Activities -1.41M -10.53M -8.13M -2.47M
Change To Operating Activities 15k 53k -95k 374k
Issuance Of Stock 111k 70k 38k 75k
Net Income 543k 3.24M 4.55M 7.76M
Change In Cash -17.88M -4.01M 2.8M 11.41M
Effect Of Exchange Rate -87k 49k -2k 62k
Total Cash From Operating Activities 8.09M 7.93M 11.69M 13.81M
Depreciation 828k 1.19M 1.21M 701k
Change To Account Receivables 11.44M 1.59M -342k 2.56M
Other Cashflows From Financing Activities -684k -744k -163k
Change To Netincome 1.83M 4.12M 4.21M 677k
Capital Expenditures -128k -796k -10k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 561k 396k 129k 88k
Income Before Tax 3.12M 5.71M 6.54M 11.06M
Net Income 543k 3.24M 4.55M 7.76M
Selling General Administrative 14.15M 7.65M 6.26M 5.11M
Gross Profit 20.44M 19.55M 18.55M 18.26M
Ebit 5.72M 11.5M 12.16M 13.06M
Operating Income 5.72M 11.5M 12.16M 13.06M
Interest Expense -907k -965k -323k -92k
Income Tax Expense 1.92M 3.07M 2.15M 3.3M
Total Revenue 22.75M 22.45M 21.61M 21.94M
Cost Of Revenue 2.31M 2.91M 3.06M 3.68M
Total Other Income ExpenseNet -2.6M -5.79M -5.63M -2M
Net Income From Continuing Ops 1.2M 2.64M 4.39M 7.76M
Net Income Applicable To Common Shares 543k 3.24M 4.55M 7.76M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 30.93M 18.44M 11.63M 12.75M
Total Stockholder Equity 24.76M 28.01M 32.64M 38.9M
Other Current Liabilities 3.76M 1.63M 2.96M 6.69M
Total Assets 55.69M 46.45M 44.28M 51.65M
Common Stock 18.32M 18.68M 18.7M 18.12M
Other Current Assets
Retained Earnings 10.62M 13.87M 18.4M 25.2M
Treasury Stock -9.51M -9.51M -9.51M -9.51M
Cash 10.36M 6.35M 9.14M 20.55M
Total Current Liabilities 21.28M 16.61M 9.92M 12.29M
Other Stockholder Equity -9.51M -9.51M -9.51M -9.51M
Property, Plant, and Equipment 690k 2.2M 1.91M 501k
Total Current Assets 22.93M 17.23M 20.13M 29.33M
Net Tangible Assets -5.08M 1.93M 12.76M 19.54M
Net Receivables 10.47M 8.88M 9.22M 6.66M
Accounts Payable 7.41M 5.24M 4.29M 2.38M


Insider Transactions

Here are the insider transactions of stock shares related to CIPHER PHARMACEUTICALS INC:

Filer Name Transaction Text Ownership Date Filer Relation Shares
Wolkin (Harold Morton)Acquisition or disposition under a purchase/ownership plan at price 2.22 per share.D2022-10-24Director of Issuer1.41k
Cipher Pharmaceuticals, Inc.Redemption, retraction, cancelation, repurchase at price 2.34 per share.D2022-09-30Issuer39.32k
Cipher Pharmaceuticals, Inc.D2022-09-30Issuer39.32k
Godin (Christian)Acquisition or disposition under a purchase/ownership plan at price 2.27 per share.D2022-09-15Director of Issuer359
Wolkin (Harold Morton)Acquisition or disposition under a purchase/ownership plan at price 2.27 per share.D2022-09-15Director of Issuer1.52k
Godin (Christian)Acquisition or disposition under a purchase/ownership plan at price 1.78 per share.D2022-08-16Director of Issuer472
Wolkin (Harold Morton)Acquisition or disposition under a purchase/ownership plan at price 1.78 per share.D2022-08-16Director of Issuer2k
Cipher Pharmaceuticals, Inc.Redemption, retraction, cancelation, repurchase at price 1.73 per share.D2022-07-31Issuer110.55k
Cipher Pharmaceuticals, Inc.D2022-07-31Issuer110.55k
Godin (Christian)Acquisition or disposition under a purchase/ownership plan at price 1.68 per share.D2022-07-15Director of Issuer493
Wolkin (Harold Morton)Acquisition or disposition under a purchase/ownership plan at price 1.68 per share.D2022-07-15Director of Issuer1.84k
Cipher Pharmaceuticals, Inc.Redemption, retraction, cancelation, repurchase at price 1.83 per share.D2022-06-30Issuer123k
Cipher Pharmaceuticals, Inc.D2022-06-30Issuer123k
Godin (Christian)Acquisition or disposition under a purchase/ownership plan at price 1.82 per share.D2022-06-15Director of Issuer461
Wolkin (Harold Morton)Acquisition or disposition under a purchase/ownership plan at price 1.82 per share.D2022-06-15Director of Issuer1.72k
Godin (Christian)Acquisition or disposition under a purchase/ownership plan at price 1.55 per share.D2022-05-20Director of Issuer461
Wolkin (Harold Morton)Acquisition or disposition under a purchase/ownership plan at price 1.55 per share.D2022-05-20Director of Issuer1.72k
Godin (Christian)Acquisition or disposition under a purchase/ownership plan at price 1.67 per share.D2022-04-20Director of Issuer439
Wolkin (Harold Morton)Acquisition or disposition under a purchase/ownership plan at price 1.67 per share.D2022-04-20Director of Issuer1.63k
Deboeck (Arthur Marie Joseph Ghislain)Exercise of rights at price 1.67 per share.D2022-04-01Director of Issuer2.5k
Gajewczyk (Diane)Exercise of rights at price 1.80 per share.D2022-04-01Senior Officer of Issuer24.6k
Gajewczyk (Diane)Exercise of rights at price 1.67 per share.D2022-04-01Senior Officer of Issuer1.55k
Godin (Christian)Exercise of rights at price 1.67 per share.D2022-04-01Director of Issuer2.5k
Mull (John D M.D.)Exercise of rights at price 1.67 per share.D2022-04-0110% Security Holder of Issuer2.5k
Mull, Craig JamesExercise of rights at price 1.67 per share.D2022-04-01Director of Issuer2.5k
Mull, Craig JamesExercise of rights at price 1.80 per share.D2022-04-01Director of Issuer14.11k
Steiner, Cathy RobinExercise of rights at price 1.67 per share.D2022-04-01Director of Issuer2.5k
Wolkin (Harold Morton)Exercise of rights at price 1.67 per share.D2022-04-01Director of Issuer7.5k
Cipher Pharmaceuticals, Inc.Redemption, retraction, cancelation, repurchase at price 1.75 per share.D2022-03-31Issuer196.3k
Cipher Pharmaceuticals, Inc.D2022-03-31Issuer196.3k
Wolkin (Harold Morton)Acquisition or disposition under a purchase/ownership plan at price 1.29 per share.D2022-03-15Director of Issuer2.07k
Wolkin (Harold Morton)Acquisition or disposition under a purchase/ownership plan at price 1.41 per share.D2022-02-15Director of Issuer1.91k
Wolkin (Harold Morton)Acquisition or disposition under a purchase/ownership plan at price 1.42 per share.D2022-01-17Director of Issuer5.12k
Cipher Pharmaceuticals, Inc.Redemption, retraction, cancelation, repurchase at price 1.42 per share.D2021-12-31Issuer156.2k
Cipher Pharmaceuticals, Inc.D2021-12-31Issuer156.2k
Cipher Pharmaceuticals, Inc.Redemption, retraction, cancelation, repurchase at price 1.82 per share.D2021-11-30Issuer161.2k
Cipher Pharmaceuticals, Inc.D2021-11-30Issuer161.2k
Wolkin (Harold Morton)Acquisition or disposition under a purchase/ownership plan at price 1.85 per share.D2021-11-15Director of Issuer1.97k
Cipher Pharmaceuticals, Inc.Redemption, retraction, cancelation, repurchase at price 2.03 per share.D2021-10-31Issuer132.8k
Cipher Pharmaceuticals, Inc.D2021-10-31Issuer132.8k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to CIPHER PHARMACEUTICALS INC. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on CIPHER PHARMACEUTICALS INC

Here is the result of two systematic investment strategies applied to CIPHER PHARMACEUTICALS INC. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on CIPHER PHARMACEUTICALS INC

The following chart shows the equity curve of the two systematic investment strategies applied to CIPHER PHARMACEUTICALS INC:

CIPHER PHARMACEUTICALS INC automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 67.28% on the backtest period.

Performance at glance

Performance

67.28 %

Latent gain

1007.79 C$

Invested capital

1497.81 C$

Annualized return

16.17 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on CIPHER PHARMACEUTICALS INC

This is the result of two momentum investment strategies applied to CIPHER PHARMACEUTICALS INC. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on CIPHER PHARMACEUTICALS INC

The following chart shows all the entries opened by the momentum investment system on CIPHER PHARMACEUTICALS INC:

CIPHER PHARMACEUTICALS INC momentum entries
  • The first momentum investment strategy would give 88.04% of return on CIPHER PHARMACEUTICALS INC. That represents 3962.59C$ of latent gain with 4500.77C$ of employed capital.
  • The second momentum investment strategy would give 94.02% of return on CIPHER PHARMACEUTICALS INC. That represents 2822.94C$ of latent gain with 3002.58C$ of employed capital.
Performance at glance (1Q Momentum)

Performance

88.04 %

Latent gain

3962.59 C$

Invested capital

4500.77 C$

Annualized return

9.74 %
Performance at glance (2Q Momentum)

Performance

94.02 %

Latent gain

2822.94 C$

Invested capital

3002.58 C$

Annualized return

25.55 %

Momentum equity curve on CIPHER PHARMACEUTICALS INC

The following chart shows the equity curve of the two momentum strategies applied to CIPHER PHARMACEUTICALS INC:

CIPHER PHARMACEUTICALS INC momentum equity

Note: the dividends potentially given by CIPHER PHARMACEUTICALS INC are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on CIPHER PHARMACEUTICALS INC

The following chart shows the employed capital evolution of the two momentum strategies on CIPHER PHARMACEUTICALS INC since the beginning:

CIPHER PHARMACEUTICALS INC

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250C$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000C$.


Buy the dip strategy result on CIPHER PHARMACEUTICALS INC

Buy the dip entry openings on CIPHER PHARMACEUTICALS INC

CIPHER PHARMACEUTICALS INC

The performance achieved by the robo-advisor on CIPHER PHARMACEUTICALS INC is 21.04%. That represents 157.66$ of latent gain with 749.46C$ of employed capital. The following chart shows CIPHER PHARMACEUTICALS INC stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of CIPHER PHARMACEUTICALS INC, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

21.04 %

Latent gain

157.66 C$

Invested capital

749.46 C$

Annualized return

9.74 %

Equity curve of the strategy applied to CIPHER PHARMACEUTICALS INC

The following chart shows the result of the investment strategy applied to CIPHER PHARMACEUTICALS INC:

CIPHER PHARMACEUTICALS INC

Note: the dividends potentially given by CIPHER PHARMACEUTICALS INC are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on CIPHER PHARMACEUTICALS INC

The following chart shows the employed capital evolution since the beginning of the investment strategy on CIPHER PHARMACEUTICALS INC:

CIPHER PHARMACEUTICALS INC

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on CIPHER PHARMACEUTICALS INC

In this section, I will compare the three previous investment strategies applied to CIPHER PHARMACEUTICALS INC.

Equity curve comparison on CIPHER PHARMACEUTICALS INC

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

CIPHER PHARMACEUTICALS INC investment strategy comparison

Employed capital comparison on CIPHER PHARMACEUTICALS INC

CIPHER PHARMACEUTICALS INC investment comparison

Performance comparison on CIPHER PHARMACEUTICALS INC

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 67.28% 1007.79C$ 1497.81C$ 16.17%
Momentum 1 quarter 88.04% 3962.59C$ 4500.77C$ 22.46%
Momentum 2 quarters 94.02% 2822.94C$ 3002.58C$ 25.55%
Non-directional 21.04% 157.66C$ 749.46C$ 9.74%
Annualized return comparison

Automatic investment

16.17 %

Momentum 1Q

25.55 %

Momentum 2Q

25.55 %

Non-directional

9.74 %

Correlated stocks

Here are the most positively and negatively correlated stocks with CIPHER PHARMACEUTICALS INC:

Note: The algorithm computes the probability of correlation between CIPHER PHARMACEUTICALS INC and the other stocks. There may be false positives or some missing correlated stocks. If the price of CIPHER PHARMACEUTICALS INC does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name CIPHER PHARMACEUTICALS INC
Country Canada
City Oakville
Address 209 Oak Park Boulevard
Phone
Website www.cipherpharma.com
FullTime employees
Industry Drug Manufacturers—Specialty & Generic
Sector Healthcare
Exchange XTSE
Ticker CPH.XTSE
Market

CIPHER PHARMACEUTICALS INC ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown